Differential physiological effects of a low dose and high doses of venlafaxine in major depression

被引:105
作者
Debonnel, Guy
Saint-Andre, Elise
Hebert, Chantal
de Montigny, Claude
Lavoie, Normand
Blier, Pierre
机构
[1] Univ Ottawa, Royal Ottawa Hosp, Mental Hlth Res Inst, Ottawa, ON K1Z 7K4, Canada
[2] McGill Univ, Dept Psychiat, Montreal, PQ, Canada
[3] McGill Univ, Dept Urol, Montreal, PQ, Canada
关键词
norepinephrine reuptake; serotonin reuptake; tyramine;
D O I
10.1017/S1461145705006413
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Venlafaxine is an antidepressant drug with demonstrated serotonin (5-HT) and norepinephrine (NE) reuptake blockade properties in electrophysiological and microdialysis experiments in laboratory animals. In healthy volunteers, its 5-HT reuptake-inhibiting potential has also been clearly documented, but not its NE reuptake blockade action. This double-blind study compared the effects of a low dose (75 mg) and of a forced titration of high (up to 375 mg in I wk) daily doses of venlafaxine. Forty-four patients with major depression according to DSM-IV criteria were assessed bi-weekly for the first 2 wk and weekly for the next 2 wk. Inhibition of 5-HT reuptake was estimated using the depletion of whole-blood 5-HT, while that of NE was assessed using the attenuation of the systolic blood-pressure elevations produced by intravenous injections of tyramine. Forty-two patients completed the study. Both the low and the high doses of venlafaxine decreased the levels of 5-HT to the same extent: the reduction was of about 55% after 1 wk and of 75% after 4 wk. The 75 mg/d dose of venlafaxine did not alter the tyramine pressor response, whereas, in patients receiving the higher regimens of venlafaxine, there was a significant attenuation of the pressor effect of tyramine. There was no significant difference between the two treatment arms regarding the modifications of the depression scores. The present data showed that, at its minimal effective dose in depression (75 mg/d), venlafaxine acted as a selective 5-HT reuptake inhibitor, whereas when administered at higher doses (225 and 375 mg/d), it acted as a dual 5-HT and NE reuptake inhibitor.
引用
收藏
页码:51 / 61
页数:11
相关论文
共 45 条
[1]  
Abdelmawla AH, 1999, BRIT J CLIN PHARMACO, V48, P345
[2]  
[Anonymous], 1987, DIAGN STAT MAN MENT
[3]   Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man [J].
Bitsios, P ;
Szabadi, E ;
Bradshaw, CM .
PSYCHOPHARMACOLOGY, 1999, 143 (03) :286-292
[4]   Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers [J].
Blier, Pierre ;
Saint-Andre, Elise ;
Hebert, Chantal ;
de Montigny, Claude ;
Lavoie, Normand ;
Debonnel, Guy .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2007, 10 (01) :41-50
[5]   PRESSOR-RESPONSES TO TYRAMINE AND NOREPINEPHRINE AFTER SUBCHRONIC ADMINISTRATION OF FLUOXETINE TO MAN [J].
BOWSHER, DJ ;
ROWE, H ;
FARID, NA ;
TENBARGE, JB ;
LEMBERGER, L .
LIFE SCIENCES, 1988, 42 (25) :2569-2575
[6]   EFFECTS OF CHRONIC TREATMENT WITH DEXFENFLURAMINE ON SEROTONIN IN RAT-BLOOD, BRAIN AND LUNG-TISSUE [J].
CELADA, P ;
MARTIN, F ;
ARTIGAS, F .
LIFE SCIENCES, 1994, 55 (15) :1237-1243
[7]   Duloxetine increases serotonin and norepinephrine availability in healthy subjects: A double-blind, controlled study [J].
Chalon, SA ;
Granier, LA ;
Vandenhende, FR ;
Bieck, PR ;
Bymaster, FP ;
Joliat, MJ ;
Hirth, C ;
Potter, WZ .
NEUROPSYCHOPHARMACOLOGY, 2003, 28 (09) :1685-1693
[8]   A DOUBLE-BLIND COMPARISON OF VENLAFAXINE AND FLUOXETINE IN PATIENTS HOSPITALIZED FOR MAJOR DEPRESSION AND MELANCHOLIA [J].
CLERC, GE ;
RUIMY, P ;
VERDEAUPAILLES, J .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1994, 9 (03) :139-143
[9]   HIGH URINARY NOREPINEPHRINE EXCRETION IN MAJOR DEPRESSIVE-DISORDERS - EFFECTS OF A NEW TYPE OF MAO INHIBITOR (MOCLOBEMIDE, RO 11-1163) [J].
DAJAS, F ;
LISTA, A ;
BARBEITO, L .
ACTA PSYCHIATRICA SCANDINAVICA, 1984, 70 (05) :432-437
[10]   Venlafaxine in treatment-resistant major depression: A Canadian multicenter, open-label trial [J].
de Montigny, C ;
Silverstone, PH ;
Debonnel, G ;
Blier, P ;
Bakish, D .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (05) :401-406